EPO (1000 IU/kg/day subcutaneously), (300 IU/kg intravenously) pre-treatment was able to attenuate the renal dysfunction and injury associated with I/R [41], [42].Administration of EPO in (1,000 IU/kg/day) rat model of type II collagen-induced arthritis tissue injury resulted in decreased proinflammatory cytokines in the circulation [43]. The gene discussed is EPO; the disease is arthritic joint disease.